NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/05/22
NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming PortfolioGlobeNewsWire • 04/08/22
NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual MeetingGlobeNewsWire • 03/08/22
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/01/22
NGM Bio's NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular DegenerationGlobeNewsWire • 02/07/22
NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic ProgramsGlobeNewsWire • 01/10/22
NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck's KEYTRUDA® (pembrolizumab)GlobeNewsWire • 12/06/21
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/04/21
NGM Biopharmaceuticals (NGM) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 11/04/21
NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology ResearchGlobeNewsWire • 08/23/21
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/06/21
NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 08/04/21
NGM Biopharma, Merck Amend Development Pact To Focus On Retinal, Cardiovascular & Metabolic TargetsBenzinga • 07/01/21
NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) DiseasesGlobeNewsWire • 07/01/21
NGM Biopharmaceuticals (NGM) Stock Jumps 7%: Will It Continue to Soar?Zacks Investment Research • 06/03/21
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 06/02/21
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 05/28/21